Biotech Catalyzed
3

ABOUT US

We focus on new uses for existing therapies and technologies. This allows us to build on existing safety profiles and leverage known mechanisms of action. The result is accelerated development and a streamlined regulatory process.

PRODUCTS

Our most advanced product addresses an unmet need in dermatology and is currently in Phase 2 testing in the U.S.
Download Presentation

PEOPLE

John Dobak, M.D.

John Dobak, M.D.

John Dobak, M.D., is the Chairman of 10xBio. He has spent the last 25 years developing novel medical technologies. Most recently he served as the CEO of DermTech, the leader in genomics and precision medicine for dermatology. Dr. Dobak has founded numerous companies and led them through development to product launch and successful exits.

Dan Piacquadio, M.D.

Dan Piacquadio, M.D.

Dan Piacquadio, M.D., is a board member and leads the clinical and regulatory development for 10xBio. Dan has over 20 years experience in developing new medical therapies and currently serves as the CEO of Therapeutics, Inc.

NEWSROOM

Get the most recent updates about 10xBio.

Recent Press Releases

10xBio Completes Series B Financing

Aug 23, 2021

SAN DIEGO (August 23, 2021) – 10xBio, LLC, a privately-held biotechnology company, completed a Series B financing from a select group of partners and private investors.

read more
Read More Press Releases

CONNECT

Thank you for your interest in 10xBio. Complete the form below and we will get back to you soon.

Name(Required)
By submitting this form, you agree to receive communications from 10xBio.
This field is for validation purposes and should be left unchanged.